Prague-based Pale Fire Capital SE added 639,162 shares of Teva in the third quarter. As of September 30, the fund reported ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best affordable healthcare stocks to buy now. Teva ...

The two updates underscore Teva’s strong execution of its Pivot to Growth strategy and commitment to financial ...

When patent protection on drugs ends, however, companies face generic competition, as competitors such as Teva make copies of the drug. Although the original drugmaker faces a painful patent cliff as ...

Teva stock climbs past $30 with strong Austedo and Ajovy sales, but shifting Wall Street sentiment may affect its outlook.

Amid a reorganization campaign that’s breathed new life into hybrid generic and innovative medicines player Teva, the company is leaning into novel medicines and formulations more than ever and ...

As the biopharma industry moves into the new year, Teva is looking to put the past behind it. After proposing a blockbuster $4.25 billion opioid settlement, the drugmaker has secured participation ...

A federal lawsuit seeking class-action status alleges that an antitrust scheme to delay releasing generic drugs originated in ...

Teva's big business is selling generic drugs. Essentially, it's the competition for makers of branded drugs once their ...

S&P upgraded Teva to BB+ and Moody's turned positive, citing falling leverage, stronger cash flow, and branded drug momentum that could support a future investment-grade rating.

The FTC investigation prompted Teva to request the removal of patents from Orange Book, paving the way for generic ...

Investing.com -- S&P Global Ratings has upgraded Teva Pharmaceutical Industries Ltd. to ’BB+’ from ’BB’ with a stable outlook ...